A5032977588- Rheumatoid Arthritis Research and Therapies
- Cytokine Signaling Pathways and Interactions
- Anesthesia and Pain Management
- Autoimmune and Inflammatory Disorders Research
- Antibiotics Pharmacokinetics and Efficacy
- Biosimilars and Bioanalytical Methods
- Monoclonal and Polyclonal Antibodies Research
- Pharmaceutical Economics and Policy
- Inflammasome and immune disorders
- Pharmacological Effects and Toxicity Studies
- Systemic Lupus Erythematosus Research
- Plant-based Medicinal Research
- Anesthesia and Sedative Agents
- Medicinal Plant Pharmacodynamics Research
- Drug Transport and Resistance Mechanisms
- Lipoproteins and Cardiovascular Health
- Pediatric Pain Management Techniques
Galapagos (France)
2024
Sanofi (France)
2019-2022
Columbus Oncology and Hematology Associates
2021
Sanofi (Mexico)
2019
We evaluated interleukin-6 (IL-6) receptor-α subunit (IL-6Rα) signaling inhibition with sarilumab and tocilizumab, the association between IL-6Rα receptor occupancy (RO) C-reactive protein (CRP), potential clinical relevance of any differences. For this, we measured binding tocilizumab in vitro, simulated soluble RO over time for approved subcutaneous (SC) intravenous (IV) SC doses, assessed associations calculated CRP reduction, 28-joint Disease Activity Score based on CRP, 20%/50%/70%...
Background: Levobupivacaine is commonly used during transversus abdominis plane (TAP) block in pediatric patients. However, the dosing regimen still empirical, and pharmacokinetic properties of levobupivacaine are not considered. Here, pharmacokinetics an ultrasound-guided TAP were evaluated to optimize regimen, regarding between-subject variability (BSV) volume injected. Method: The clinical trial (prospective, randomized, double-blind study protocol) was conducted 40 children aged 1–5...
Background Objectives The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15- to 22-fold higher than tocilizumab.1 We explored relationship between IL-6R RO, relevant pharmacodynamic (PD) variables (eg CRP), and potential clinical relevance differences tocilizumab. Methods Binding total soluble (sIL-6R) vivo translates into quasi-steady-state target-mediated drug disposition pharmacokinetics (PK) indirect-response PD model with inhibition...
Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the prevention of cardiovascular risk and exhibiting target-mediated drug disposition (TMDD). The aim this work was to develop an integrated pharmacokinetic-pharmacodynamic model describe interaction alirocumab with PCSK9 its impact on evolution low-density lipoprotein cholesterol (LDL-C) levels explore labeling specification for subpopulations.Using data...
Abstract Background Tyrosine kinase 2 (TYK2), a Janus (JAK) family member, is attracting lot of interest as new target to treat patients with autoimmune and inflammatory diseases, including bowel disease, several inhibitors are currently in clinical development. In vitro pharmacological profiling TYK2 has been employed evaluate potency selectivity; however, such data best viewed relation exposure levels. We compared expected levels inhibition TYK2-dependent -independent pathways for...
This study provides a physiologically based pharmacokinetic (PBPK) model-based analysis of the potential drug–drug interaction (DDI) between cyclosporin A (CsA), breast cancer resistance protein transporter (BCRP) inhibitor, and methotrexate (MTX), putative BCRP substrate. PBPK models for CsA MTX were built using open-source tools published data both model building verification validation. The evaluated their application in simulating BCRP-related DDIs. qualification an introduced empirical...